Please login to the form below

AMD

This page shows the latest AMD news and features for those working in and with pharma, biotech and healthcare.

Alector kicks off next wave of biotech IPOs

In December the Boston-based company gained a valuable FDA fast track designation for its lead candidate, elamipretide, a treatment for dry age-related macular degeneration (AMD), for which there are

Latest news

Bayer to challenge Avastin legal ruling

age-related macular degeneration (wet AMD) in place of two licensed but much more expensive treatments, Bayer’s Eylea and Novartis’ Lucentis. ... The NHS in England spends around £500m on licensed wet AMD treatments every year, with around £300m
After Lucentis setback, Novartis trumpets data on follow-up drug

of Lucentis and Eylea for AMD, even though Avastin isn’t approved for the indication. ... Meanwhile, Eylea has been gaining ground in wet AMD thanks to less frequent dosing, accord to GlobalData.
NHS wins legal fight with pharma over off-label Avastin

and Novartis’ Lucentis to treat wet AMD, claiming that it broke EU and UK laws governing medicines licensing. ... CCGs across the country have been thwarted in their various attempts to introduce the cheaper but equally effective drug Avastin for
Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Bayer's Eylea remains the drug to beat, however. Allergan has positive phase III results for a wet age-related macular degeneration (AMD) drug that seems to be at least as ... The new drug could halve the number of injections into the eye that are needed
Joerg Moeller to head Bayer R&D after operational shake-up

The company has suffered a few R&D disappointments of late, however, including the failures of a Regeneron-partnered combination therapy for age-related macular degeneration (AMD) and a drug-device

More from news
Approximately 23 fully matching, plus 67 partially matching documents found.

Latest Intelligence

Deal Watch October 2018

RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... Effectively the deal is structured as an option, as the phase 2 study in dry AMD will be
30 Women Leaders in UK Healthcare (part 2)

treatments for age-related macular degeneration (AMD).
The good, the bad and the ugly

In the EU, where there’s a high prevalence of AMD, Bayer has enjoyed great success with Eylea - growing revenues by 18% in 2017,” says Alice Stevens, analyst, cardiovascular and metabolic ... The company plans to launch the highly anticipated
Working with our healthcare system more closely is vital

to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD).
Deal Watch November 2015

The acquisition brings an ophthalmology focus with products for Stargardt's macular degeneration, dry AMD, and myopic macular degeneration. ... 380. Ocata Therapeutics. Astellas Pharma| Laurel. Acquisition - company. Regenerative medicine pipeline focus

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

Gyroscope Therapeutics appoints CEO

Gyroscope has a unique translational approach to tackling complex diseases such as dry AMD for which there are no therapies today.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Digital Account Director: Salary TBC

Senior Medical Writer: Great salary and benefits

Senior Medical Writer: Salary TBC

Project Manager/ Account Manager: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Director, Healthcare Marketing Agency: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

International Childhood Cancer Day 2019: The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues: Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups: A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...